Assistant Director, Data Sciences and Analytics, with Tufts Center for the Study of Drug Development (Tufts CSDD)
Limited evidence surrounds direct-to-patient clinical trial site models, despite growing literature showing that decentralized approaches can improve patient access, enrollment performance, and operational efficiency while reducing participant burden.
Insights identify opportunities to optimize sponsor, CRO, and site collaborations.
Pilot study seeks to validate new and more granular outsourcing model classifications in differentiating performance across custom contract-service approaches.
Tufts CSDD study in collaboration with ten biopharmaceutical organizations and CROs examines sponsor/CRO relationships.
2020 Tufts CSDD – IBM Watson Health benchmarking study highlights need for new functionality from EDC solutions and providers.